[目的]探讨尼妥珠单抗同期调强放疗及化疗治疗食管癌的疗效及不良反应。[方法]经病理确诊的食管癌初诊患者32例分为两组,对照组(n=16)采用调强放疗及化疗;观察组(n=16)除调强放疗及化疗外,每周放疗前进行尼妥珠单抗100mg治疗,共6~7次。[结果]放疗结束后2个月复查完全缓解(CR)率,观察组为87.5%,对照组为68.8%,两组有效(RR)率均为100.0%;随访2年对照组和观察组的局部区域控制率为87.5%和100%(P>0.05),而无远处转移生存率分别为62.5%和81.3%(P>0.05)。两组主要不良反应为放射性食管黏膜炎、放射性皮炎和恶心呕吐、粒细胞减少、疲乏等,无皮疹及过敏反应发生,患者均能耐受,观察组发生2级以上放射性食管黏膜炎、粒细胞减少较对照组偏高,但差异无统计学意义(P>0.05)。[结论]尼妥珠单抗可提高食管癌对放疗的敏感性,提高有效率及降低复发转移率,安全有效。 [Objective] To investigate the efficacy and side effects of nimotuzumab in the treatment of esophageal cancer with intensity-modulated radiotherapy and chemotherapy. [Method] Thirty-two newly diagnosed esophageal cancer patients were divided into two groups. The control group (n = 16) received IMRT and chemotherapy. In the observation group (n = 16) Before nimotuzumab 100mg treatment, a total of 6 to 7 times. [Results] The complete remission (CR) rate was 2 months after the end of radiotherapy. The observation group and the control group were 87.5% and 68.8% respectively. The RR rates of both groups were 100.0% The regional control rates were 87.5% and 100% respectively (P> 0.05), while the distant metastasis-free survival rates were 62.5% and 81.3% (P> 0.05). The two groups of major adverse reactions were radiation esophageal mucositis, radiation dermatitis and nausea and vomiting, neutropenia, fatigue, etc., no rash and allergic reactions occurred, patients were able to tolerate the observation group occurred more than 2 radioactive esophagitis, granulocytes Reduce more than the control group, but the difference was not statistically significant (P> 0.05). [Conclusion] Nimotuzumab can improve esophageal cancer sensitivity to radiation, improve efficiency and reduce the rate of recurrence and metastasis, safe and effective.